What is Regeneron Pharmaceuticals's PP&E (net)?

Regeneron Pharmaceuticals (REGN) reported PP&E (net) of $5.46B in Q2 2026.

What is the long-term trend for Regeneron Pharmaceuticals's PP&E (net)?

Over 2 years (2020 to 2025), Regeneron Pharmaceuticals's PP&E (net) has grown at a 26.1% compound annual growth rate (CAGR), from $3.22B to $5.12B.

What does PP&E (net) mean?

Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.

Regeneron Pharmaceuticals REGN PP&E (Net)

PP&E (Net) at other companies

Merck & Co.MRK

$25.43B+2.6%

AmgenAMGN

$8.22B+23.0%

GlaukosGKOS

$112.11M+0.3%

EyePoint, Inc. EYPT

$9.48M+17.9%

PrecigenPGEN

$13.22M-9.9%

Ocular TherapeutixOCUL

$18.43M+70.9%

Segments

By geography

See full

Outside United States$788M+10.1%

Other financials

Income statement

See full

Revenue$4.3B+16.7%

Operating income$1.3B+19.8%

Net income$1.3B-6.8%

EPS (diluted)$12.23-4.5%

Balance sheet

See full

Cash & equivalents$2.5B+22.3%

Total debt$2.7B+0.1%

Total equity$31.7B+5.9%

Total assets$41.7B+9.2%

Cash flow

See full

Operating cash flow$813.0M-29.0%

CapEx$240.2M+9.7%

Free cash flow$572.8M-38.1%

Valuation

See full

Market cap$72.88B+21.8%

Enterprise value$73.12B+20.8%

P/E16.8×+3.4×

P/S4.7×+0.5×

Profitability

See full

Gross margin94.9%—

Operating margin24.7%-2.3pp

Net margin27.9%-3.5pp

FCF margin24.2%-2.9pp

Returns & leverage

See full

Return on equity14%-1.3pp

Debt / equity0.1×0.0×

Current ratio3.3×-1.3×

Where this comes from

Reported directly by Regeneron Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization.

The official record: Regeneron Pharmaceuticals’s 10-Q, filed July 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Regeneron Pharmaceuticals's pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Regeneron Pharmaceuticals's PP&E (net)?: Regeneron Pharmaceuticals (REGN) reported PP&E (net) of $5.46B in Q2 2026.
What is the long-term trend for Regeneron Pharmaceuticals's PP&E (net)?: Over 2 years (2020 to 2025), Regeneron Pharmaceuticals's PP&E (net) has grown at a 26.1% compound annual growth rate (CAGR), from $3.22B to $5.12B.
What does PP&E (net) mean?: Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.